Busy. Please wait.
Log in with Clever
or
show password
Forgot Password?
Don't have an account?  Sign up 
Sign up using Clever
or
Username is available taken
show password

Your email address is only used to allow you to reset your password. See our Privacy Policy and Terms of Service.

Already a StudyStack user? Log In

Reset Password
Enter the associated with your account, and we'll email you a link to reset your password.

Lecture 31 Test

Enter the letter for the matching Answer
incorrect
1.
How is LMWH excreted?
incorrect
2.
What is the half-life of Lepirudin?
incorrect
3.
(T or F) Methylene tetrahydrofolate reductase results in primary elevated homocysteine levels.
incorrect
4.
What is the mechanism of Lepirudin?
incorrect
5.
What are the contraindications to thrombolytic therapy?
incorrect
6.
What pharmacologic agents are indirect Factor Xa Inhibitors?
incorrect
7.
How are the anticoagulant effects monitored by LMWH?
incorrect
8.
What is the half-life of Fondaparinux (Arixtra)?
incorrect
9.
What type of clot is platelet rich and white in appearance?
incorrect
10.
What is the suggested evaluation for arterial thrombosis?
incorrect
11.
How is Bivalirudin administered?
incorrect
12.
What is the mechanism of Argatroban?
incorrect
13.
What pharmalogical agent reverses the effects of heparin?
incorrect
14.
What is the half-life of heparin?
incorrect
15.
Are the anticoagulant effects of Argatroban reversible?
incorrect
16.
What is the suggested evaluation for venous thromboembolism in a patient with no previous family or personal history?
incorrect
17.
What is the mechanism of Bivalirudin?
incorrect
18.
Factor Xa to Factor IIa activity of unfractionated heparin vs. low molecular weight heparin
incorrect
19.
What are the complications of warfarin therapy?
incorrect
20.
(T or F) LMWH never need monitoring.
A.
Varies by dose (average is 1-2 hours)
B.
Aterial thromi
C.
IV
D.
1)Major internal bleeding in the last 6 mo 2)Intracranial or intraspinal disease 3)Operation or biopsy in the preceding 10 days 4)HTN (sys >200, dia>110) 5)Active endocarditis 6)Pericarditis 7)Aneurysm 8)Presence of bleeding disorder
E.
Anti-Xa assay
F.
UFH= 1:1 vs. LMWH 4:1 - 2:1 (LMWH have less than 19 saccharide units therefore they lack thrombin inhibition)
G.
True.
H.
Renally
I.
Irreversible Direct Thrombin (IIa) Inhibitors
J.
1)Heparin 2)Low Molecular Weight Heparin 3)Fondaparinux
K.
15-18 hours
L.
False. Patients with changing or decreased kidney function must be monitored. Also, very large or very small and pregnant patients may need dose adjustments
M.
1)Bleeding 2)Warfarin induced skin necrosis 3)Cholestatic jaundice 4)Nausea/vomiting 5)Alopecia 6)Mouth ulcers 7)Rash
N.
No
O.
1)Lupus anticoagulant and anticardiolipin Ab 2)Homocysteine level 3)Lipid levels 4)Rule out estrogen and vasculitic risk factors
P.
Reversible Direct Thrombin (FIIa) Inhibitor
Q.
1)Lupus anticoagulant and anticardiolipin Ab 2)Homocysteine level 3)Consider Factor V Leiden, Factor II mutation, Factor VIII level, Fibrinogen studies 3)Rule out estrogen and vasculitic risk factors
R.
Reversible Direct Thrombin(IIa) Inhibitors
S.
Protamine
T.
1.5 hours
Type the Answer that corresponds to the displayed Question.
incorrect
21.
What is the half-life of warfarin?
incorrect
22.
What is the half-life of LMWH?
incorrect
23.
How is Lepirudin excreted?
incorrect
24.
What is the half-life of Argatroban?
incorrect
25.
How is Bivalirudin excreted?
incorrect
26.
How is fondaparinux excreted?
incorrect
27.
What is the half-life of Bivalirudin?
incorrect
28.
Approximately what percentage of proximal DVTs are associated with pulmonary embolism?
incorrect
29.
How is heparin administered?
incorrect
30.
How are the anticoagulant effects monitored by fondaparinux (Arixtra)?

edit
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.

  Normal Size     Small Size show me how
Created by: UVAPATH4
Popular Medical sets